Chronos Archive seal
The Human Record

Yul Brynner

Case HR-ML020 · Modern EHR teaching episode · Draft for review

Review summary

Historical dates
July 11, 1920 – October 10, 1985
Synthetic DOB
1963-07-11
Index visit
2026-09-01 at age 63
Synthetic MRN
HR-ML020-SYN

Teaching objective: Work up hoarseness from left vocal fold paralysis in a 63-year-old former heavy smoker to a tissue diagnosis of advanced nonsquamous non-small cell lung cancer; stage it with PET-CT and brain MRI; obtain PD-L1 and comprehensive tissue and plasma biomarker testing before choosing first-line systemic therapy (pembrolizumab for PD-L1 70 percent with no actionable alteration); monitor for immune-related adverse events with TSH, free T4, liver tests, glucose, and cortisol as indicated, and evaluate a rash on treatment; start a bone-modifying agent safely; integrate palliative care early (ASCO 2017) with symptom and distress screening; record the tobacco history; begin advance care planning; and support his wish to keep performing, on the CMID lung cancer schedule and NCCN guidance.

Historical timeline

DateEventClaims
July 11, 1920Born in Vladivostok, by the documented account; he later gave other birthplaces and years.CLM-0001, CLM-0002
1951First plays the King in The King and I on Broadway; Academy Award for the 1956 film.CLM-0003
1971Quits smoking after decades of heavy use.CLM-0004
September 1983Found to have lung cancer that cannot be removed surgically; treated that month and vows to resume touring.CLM-0005
summer 1985Last performance as the King in New York, about two years after the diagnosis.CLM-0006, CLM-0007
October 10, 1985Dies in New York at 65 of complications of cancer; an anti-smoking message he recorded is broadcast after his death.CLM-0008, CLM-0009

Evidence claims

D = documented, R = retrospective, S = synthetic.

GradeClaimCertaintySources
D Yul Brynner was born Yuliy Borisovich Bryner on July 11, 1920, in Vladivostok, Russia.
The documented date used for the synthetic date of birth; it agrees with his age of 65 at death in contemporary obituaries. He gave other accounts himself (see CLM-0002).
probable Yul Brynner supports
Yul Brynner, exotic actor (obituary) supports
Milestones, Oct. 21, 1985 supports
D He gave varying accounts of his origins, saying at times that he was born on Sakhalin Island, with the year given as 1915 (UPI gives July 11, 1915; another reference gives July 12, 1915, under the name Taidje Kahn).
The conflicting accounts are his own; they are recorded as rejected alternatives to the documented date.
confirmed Yul Brynner, exotic actor (obituary) supports
Brynner's final bow supports
Brynner, Yul supports
Milestones, Oct. 21, 1985 supports
D He first played the King of Siam in The King and I on Broadway in 1951, won the Academy Award for best actor in the 1956 film, and played the role 4,625 times over 34 years.
Used for the synthetic modern occupation (stage actor and singer on tour).
confirmed Yul Brynner supports
Milestones, Oct. 21, 1985 supports
Yul Brynner, exotic actor (obituary) supports
D He smoked heavily for decades: UPI reported that at one time he smoked five packs of cigarettes a day, and Cancer Today reports two to four packs a day from the age of 12 and that he quit in 1971.
The amounts differ between sources; the quit year is from one source. Used for the former-smoker history; the pack-year estimate in the modern record is synthetic.
probable Brynner's final bow supports
'Don't smoke, whatever you do' supports
Rochman S. Yul Brynner (Cancer Today) supports
D In September 1983 he was found to have lung cancer; Cancer Today reports that he had found a lump on his vocal cords and that the tumor was too close to his heart for surgery, and UPI reports that he was treated for lung cancer that month and said he would beat the disease and resume touring.
The diagnosis month and the inoperable tumor are consistent across sources; the voice complaint and the place of treatment are from single sources. Anchors the synthetic presentation with hoarseness and an unresectable left upper lobe cancer.
probable Rochman S. Yul Brynner (Cancer Today) supports
Yul Brynner, exotic actor (obituary) supports
D He returned to the stage and kept playing the King for about two more years; his last performance came in New York in the summer of 1985, less than four months before his death.
UPI gives July 2 for the farewell performance; other accounts give June 30. The case uses summer 1985. Used for the goal of supporting him to keep working.
confirmed Yul Brynner, exotic actor (obituary) supports
Brynner's final bow supports
Milestones, Oct. 21, 1985 supports
D He said in an interview that he believed his cancer was directly caused by smoking, calling smoking "suicide."
His own public statement.
confirmed Brynner's final bow supports
D After his death the American Cancer Society released a 30-second television message taken from a January 1985 Good Morning America interview, in which he says: "Now that I'm gone, I tell you: Don't smoke, whatever you do. Just don't smoke."
UPI reports that it first aired on ABC in February 1986, about four months after his death; Cancer Today says networks ran it within days of his death. The case records both and uses neither date in the episode.
confirmed 'Don't smoke, whatever you do' supports
Rochman S. Yul Brynner (Cancer Today) supports
Brynner, Yul supports
D He died on October 10, 1985, at 65, at New York Hospital-Cornell Medical Center, of complications of cancer.
History only; after the true-frame episode.
confirmed Yul Brynner, exotic actor (obituary) supports
Yul Brynner supports
Milestones, Oct. 21, 1985 supports

Modern synthetic problem list

GradeProblemClinical statusVerificationPlacementHistorical claims
S Adenocarcinoma of the left upper lobe of the lung, stage IVB (cT4 N2 M1c, AJCC 8th edition), unresectable: the primary invades the mediastinum at the aortopulmonary window; bone metastases; PD-L1 tumor proportion score 70 percent (22C3); ECOG performance status 1; comprehensive genomic profiling results in the notes active confirmed both_with_link CLM-0005, CLM-0006
S Bone metastases at T10, the right ilium, and the left sixth rib on PET-CT, without pain, fracture, or cord compression active confirmed active CLM-0005, CLM-0006
S Left vocal fold paralysis with a breathy, weak voice, most likely from left recurrent laryngeal nerve involvement by disease in the aortopulmonary window active confirmed both_with_link CLM-0005
S Left upper lobe mass invading the mediastinum, with enlarged mediastinal lymph nodes, on CT at presentation; suspicious for lung cancer pending tissue diagnosis active confirmed active CLM-0005, CLM-0006
S Former smoker: about 3 packs a day from age 12 until he quit 12 years ago, roughly 115 pack-years; no tobacco since active confirmed both_with_link CLM-0004, CLM-0007
S Immune-related maculopapular rash from pembrolizumab, grade 1 (about 8 percent of body surface area, itchy, no blisters or mucosal involvement) active confirmed active

Synthetic outcome measures

GradeDateMeasureResultCoding
S 2026-09-01 Hemoglobin [Mass/volume] in Blood 13.8 g/dL
Reference 13.5-17.5 g/dL
http://loinc.org · 718-7
S 2026-09-01 Leukocytes [#/volume] in Blood by Automated count 7.9 10*3/uL
Reference 4-11 10*3/uL
http://loinc.org · 6690-2
S 2026-09-01 Platelets [#/volume] in Blood by Automated count 290 10*3/uL
Reference 150-400 10*3/uL
http://loinc.org · 777-3
S 2026-09-01 Sodium [Moles/volume] in Serum or Plasma 138 mmol/L
Reference 135-145 mmol/L
http://loinc.org · 2951-2
S 2026-09-01 Potassium [Moles/volume] in Serum or Plasma 4.3 mmol/L
Reference 3.5-5.1 mmol/L
http://loinc.org · 2823-3
S 2026-09-01 Creatinine [Mass/volume] in Serum or Plasma 0.9 mg/dL
Reference 0.7-1.3 mg/dL
http://loinc.org · 2160-0
S 2026-09-01 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 92 mL/min/1.73 m²
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 2026-09-01 Calcium [Mass/volume] in Serum or Plasma 9.6 mg/dL
Reference 8.6-10.3 mg/dL
http://loinc.org · 17861-6
S 2026-09-01 Albumin [Mass/volume] in Serum or Plasma 4 g/dL
Reference 3.5-5 g/dL
http://loinc.org · 1751-7
S 2026-09-01 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 24 U/L
Reference 7-55 U/L
http://loinc.org · 1742-6
S 2026-09-01 Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 22 U/L
Reference 8-48 U/L
http://loinc.org · 1920-8
S 2026-09-01 Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 98 U/L
Reference 40-129 U/L
http://loinc.org · 6768-6
S 2026-09-01 Bilirubin.total [Mass/volume] in Serum or Plasma 0.6 mg/dL
Reference 0.1-1.2 mg/dL
http://loinc.org · 1975-2
S 2026-09-01 Glucose [Mass/volume] in Serum or Plasma 96 mg/dL
Reference 70-99 mg/dL
http://loinc.org · 2345-7
S 2026-09-01 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 5 http://loinc.org · 44261-6
S 2026-09-15 Total score [Edmonton Symptom Assessment System] 18 http://loinc.org · 112493-2
S 2026-09-22 Thyrotropin [Units/volume] in Serum or Plasma 2.1 mIU/L
Reference 0.4-4 mIU/L
http://loinc.org · 3016-3
S 2026-09-22 Thyroxine (T4) free [Mass/volume] in Serum or Plasma 1.2 ng/dL
Reference 0.8-1.8 ng/dL
http://loinc.org · 3024-7
S 2026-09-22 Cortisol [Mass/volume] in Serum or Plasma 14.2 ug/dL
Reference Morning (8 a.m.) reference interval
http://loinc.org · 2143-6
S 2026-09-22 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 26 U/L
Reference 7-55 U/L
http://loinc.org · 1742-6
S 2026-09-22 Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 23 U/L
Reference 8-48 U/L
http://loinc.org · 1920-8
S 2026-09-22 Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 101 U/L
Reference 40-129 U/L
http://loinc.org · 6768-6
S 2026-09-22 Bilirubin.total [Mass/volume] in Serum or Plasma 0.6 mg/dL
Reference 0.1-1.2 mg/dL
http://loinc.org · 1975-2
S 2026-09-22 Creatinine [Mass/volume] in Serum or Plasma 0.9 mg/dL
Reference 0.7-1.3 mg/dL
http://loinc.org · 2160-0
S 2026-09-22 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 92 mL/min/1.73 m²
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 2026-09-22 Glucose [Mass/volume] in Serum or Plasma 94 mg/dL
Reference 70-99 mg/dL
http://loinc.org · 2345-7
S 2026-09-22 Calcium [Mass/volume] in Serum or Plasma 9.5 mg/dL
Reference 8.6-10.3 mg/dL
http://loinc.org · 17861-6
S 2026-09-22 Hemoglobin [Mass/volume] in Blood 13.6 g/dL
Reference 13.5-17.5 g/dL
http://loinc.org · 718-7
S 2026-09-22 Leukocytes [#/volume] in Blood by Automated count 7.6 10*3/uL
Reference 4-11 10*3/uL
http://loinc.org · 6690-2
S 2026-09-22 Platelets [#/volume] in Blood by Automated count 284 10*3/uL
Reference 150-400 10*3/uL
http://loinc.org · 777-3
S 2026-10-13 Thyrotropin [Units/volume] in Serum or Plasma 2.4 mIU/L
Reference 0.4-4 mIU/L
http://loinc.org · 3016-3
S 2026-10-13 Thyroxine (T4) free [Mass/volume] in Serum or Plasma 1.1 ng/dL
Reference 0.8-1.8 ng/dL
http://loinc.org · 3024-7
S 2026-10-13 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 30 U/L
Reference 7-55 U/L
http://loinc.org · 1742-6
S 2026-10-13 Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 27 U/L
Reference 8-48 U/L
http://loinc.org · 1920-8
S 2026-10-13 Bilirubin.total [Mass/volume] in Serum or Plasma 0.7 mg/dL
Reference 0.1-1.2 mg/dL
http://loinc.org · 1975-2
S 2026-10-13 Creatinine [Mass/volume] in Serum or Plasma 0.9 mg/dL
Reference 0.7-1.3 mg/dL
http://loinc.org · 2160-0
S 2026-10-13 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 92 mL/min/1.73 m²
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 2026-10-13 Glucose [Mass/volume] in Serum or Plasma 104 mg/dL (high)
Reference 70-99 mg/dL
http://loinc.org · 2345-7
S 2026-10-13 Calcium [Mass/volume] in Serum or Plasma 9.4 mg/dL
Reference 8.6-10.3 mg/dL
http://loinc.org · 17861-6
S 2026-10-13 Hemoglobin [Mass/volume] in Blood 13.5 g/dL
Reference 13.5-17.5 g/dL
http://loinc.org · 718-7
S 2026-10-13 Leukocytes [#/volume] in Blood by Automated count 7.2 10*3/uL
Reference 4-11 10*3/uL
http://loinc.org · 6690-2
S 2026-10-13 Platelets [#/volume] in Blood by Automated count 270 10*3/uL
Reference 150-400 10*3/uL
http://loinc.org · 777-3
S 2026-10-13 Total score [Edmonton Symptom Assessment System] 12 http://loinc.org · 112493-2
S 2026-10-13 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 4 http://loinc.org · 44261-6
S 2026-10-20 Thyrotropin [Units/volume] in Serum or Plasma 2.6 mIU/L
Reference 0.4-4 mIU/L
http://loinc.org · 3016-3
S 2026-10-20 Thyroxine (T4) free [Mass/volume] in Serum or Plasma 1.1 ng/dL
Reference 0.8-1.8 ng/dL
http://loinc.org · 3024-7
S 2026-10-20 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 28 U/L
Reference 7-55 U/L
http://loinc.org · 1742-6
S 2026-10-20 Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 25 U/L
Reference 8-48 U/L
http://loinc.org · 1920-8
S 2026-10-20 Bilirubin.total [Mass/volume] in Serum or Plasma 0.6 mg/dL
Reference 0.1-1.2 mg/dL
http://loinc.org · 1975-2
S 2026-10-20 Creatinine [Mass/volume] in Serum or Plasma 0.9 mg/dL
Reference 0.7-1.3 mg/dL
http://loinc.org · 2160-0
S 2026-10-20 Eosinophils [#/volume] in Blood by Automated count 0.62 10*3/uL (high)
Reference 0-0.5 10*3/uL
http://loinc.org · 711-2
S 2026-10-27 Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 1 http://loinc.org · 55758-7
S 2026-10-27 Total score [AUDIT-C] 2 http://loinc.org · 75626-2

Synthetic vital signs

DateMeasureResultLOINCGrade
2026-09-01Body height178 cm8302-2S
2026-09-01Body weight72.4 kg29463-7S
2026-09-01Body mass index (BMI) [Ratio]22.9 kg/m239156-5S
2026-09-01Systolic blood pressure132 mm[Hg]8480-6S
2026-09-01Diastolic blood pressure80 mm[Hg]8462-4S
2026-09-01Heart rate82 /min8867-4S
2026-09-01Respiratory rate16 /min9279-1S
2026-09-01Body temperature36.8 Cel8310-5S
2026-09-01Oxygen saturation in Arterial blood by Pulse oximetry96 %59408-5S
2026-09-15Body height178 cm8302-2S
2026-09-15Body weight72 kg29463-7S
2026-09-15Body mass index (BMI) [Ratio]22.7 kg/m239156-5S
2026-09-15Systolic blood pressure128 mm[Hg]8480-6S
2026-09-15Diastolic blood pressure78 mm[Hg]8462-4S
2026-09-15Heart rate80 /min8867-4S
2026-09-15Respiratory rate16 /min9279-1S
2026-09-15Body temperature36.7 Cel8310-5S
2026-09-15Oxygen saturation in Arterial blood by Pulse oximetry96 %59408-5S
2026-09-22Body height178 cm8302-2S
2026-09-22Body weight71.8 kg29463-7S
2026-09-22Body mass index (BMI) [Ratio]22.7 kg/m239156-5S
2026-09-22Systolic blood pressure126 mm[Hg]8480-6S
2026-09-22Diastolic blood pressure78 mm[Hg]8462-4S
2026-09-22Heart rate78 /min8867-4S
2026-09-22Respiratory rate16 /min9279-1S
2026-09-22Body temperature36.6 Cel8310-5S
2026-09-22Oxygen saturation in Arterial blood by Pulse oximetry96 %59408-5S
2026-10-13Body height178 cm8302-2S
2026-10-13Body weight72.2 kg29463-7S
2026-10-13Body mass index (BMI) [Ratio]22.8 kg/m239156-5S
2026-10-13Systolic blood pressure124 mm[Hg]8480-6S
2026-10-13Diastolic blood pressure76 mm[Hg]8462-4S
2026-10-13Heart rate76 /min8867-4S
2026-10-13Respiratory rate16 /min9279-1S
2026-10-13Body temperature36.7 Cel8310-5S
2026-10-13Oxygen saturation in Arterial blood by Pulse oximetry97 %59408-5S
2026-10-20Body height178 cm8302-2S
2026-10-20Body weight72 kg29463-7S
2026-10-20Body mass index (BMI) [Ratio]22.7 kg/m239156-5S
2026-10-20Systolic blood pressure126 mm[Hg]8480-6S
2026-10-20Diastolic blood pressure78 mm[Hg]8462-4S
2026-10-20Heart rate78 /min8867-4S
2026-10-20Respiratory rate16 /min9279-1S
2026-10-20Body temperature36.7 Cel8310-5S
2026-10-20Oxygen saturation in Arterial blood by Pulse oximetry97 %59408-5S
2026-10-27Body height178 cm8302-2S
2026-10-27Body weight72.3 kg29463-7S
2026-10-27Body mass index (BMI) [Ratio]22.8 kg/m239156-5S
2026-10-27Systolic blood pressure124 mm[Hg]8480-6S
2026-10-27Diastolic blood pressure76 mm[Hg]8462-4S
2026-10-27Heart rate74 /min8867-4S
2026-10-27Respiratory rate16 /min9279-1S
2026-10-27Body temperature36.6 Cel8310-5S
2026-10-27Oxygen saturation in Arterial blood by Pulse oximetry97 %59408-5S

Social, functional, and mental status

Social history

Functional status

Mental status

Allergies and medications

Allergies

Medications

Procedures and immunizations

Procedures

Immunizations

Past medical history

True biography with historical dates; not part of the synthetic care timeline.

Family history

No family medical history is documented in the logged sources. Family history of real relatives is never synthesized.

Care-plan goals

GoalTarget dateStatusOutcome
Tissue diagnosis, full staging, PD-L1, and comprehensive biomarker results before any systemic therapy, within three weeks of presentation2026-09-22completedDiagnosis and stage by two weeks; PD-L1 at two weeks and tissue sequencing at three weeks; pembrolizumab started the day the sequencing was reviewed
First palliative care visit within eight weeks of diagnosis2026-10-13completedSeen by the palliative care team two weeks after diagnosis
A voice strong enough for rehearsal by the second cycle2026-10-13completedLouder, less breathy voice one week after injection medialization; light rehearsal resumed with voice therapy
No grade 2 or higher immune-related adverse event missed: laboratory panel before each infusion and symptom review at each visit2026-10-13completedPanels normal before cycles 1 and 2; no symptoms of colitis, pneumonitis, hepatitis, or endocrine dysfunction
Zoledronic acid started only after a dental examination and normal calcium and kidney function2026-10-13completedDental examination three weeks earlier; calcium 9.4 and eGFR 92; first dose with cycle 2

Interventions

InterventionStatusGuideline
Thoracic oncology consultation for the tissue diagnosis, stage, biomarker plan, first-line therapy, the place of radiation and a bone-modifying agent, and monitoringcompletedGL-CMID-2026, GL-NCCN-NSCLC-2026
Staging and tissue diagnosis: FDG PET-CT, brain MRI with contrast, and endobronchial ultrasound-guided needle aspiration of the highest-stage node, with enough tissue for PD-L1 and comprehensive next-generation sequencing, and plasma cell-free DNA testing in parallelcompletedGL-CMID-2026, GL-NCCN-NSCLC-2026
First-line systemic therapy chosen by biomarkers once sequencing excludes an actionable alteration: pembrolizumab 200 mg every 3 weeks for PD-L1 50 percent or more, with response CT every 6 to 12 weeks; switch to 400 mg every 6 weeks to fit the tour once stablecompletedGL-CMID-2026, GL-NCCN-NSCLC-2026
Immune-related adverse event monitoring: TSH and free T4, liver tests, creatinine, glucose, and blood count before each infusion; morning cortisol at baseline and for symptoms; written list of warning symptoms (diarrhea, cough or breathlessness, rash, yellowing, severe fatigue or headache) with a 24-hour oncology telephone linecompletedGL-ASCO-IRAE-2021, GL-CMID-2026
Early integrated palliative care alongside cancer treatment, starting within eight weeks of diagnosis, with symptom (ESAS) and distress screening at each visit and advance care planningcompletedGL-ASCO-PALL-2017, GL-NCCN-DISTRESS-2026, GL-CMID-2026
If bone metastases are confirmed: zoledronic acid 4 mg every 12 weeks after a dental examination, with calcium and vitamin D and calcium and creatinine checks before each dose; palliative radiation only if a lesion becomes painful or threatens fracturecompletedGL-CMID-2026, GL-NCCN-NSCLC-2026
Voice and work: injection medialization of the left vocal fold, voice therapy with a speech-language pathologist, infusions scheduled on his day off, and a graded return to rehearsal and performance as he choosescompletedGL-CMID-2026, GL-NCCN-NSCLC-2026
Tobacco: confirm abstinence at each visit; no cessation treatment needed; record the smoking history for his care teamcompletedGL-CMID-2026, GL-NCCN-NSCLC-2026

Planned encounters

Supporting documents

C-CDA note documents

Each link opens a readable copy; the XML beside it is the exchange file.

Sources

IDSourcePublisherType
SRC-0001 Yul Brynner, exotic actor (obituary) United Press International other
SRC-0002 Brynner's final bow United Press International other
SRC-0003 'Don't smoke, whatever you do' United Press International other
SRC-0004 Rochman S. Yul Brynner (Cancer Today) American Association for Cancer Research other
SRC-0005 Milestones, Oct. 21, 1985 TIME other
SRC-0006 Yul Brynner Biography.com (A&E Television Networks) biography
SRC-0007 Brynner, Yul Encyclopedia.com (International Dictionary of Films and Filmmakers) biography
SRC-0008 HISTMED Master Roster v3 The Human Record project other

Review status

ReviewStatusNotes
schema validationnot_startedRun scripts/build.ps1 -Conformance.
clinical reviewnot_startedAwaiting clinician review; check the stage, the biomarker sequence (therapy started only after tissue sequencing), the choice of pembrolizumab monotherapy, the immune-related adverse event monitoring, the rash evaluation at the sick visit, and the deviation recorded for the missed symptom screen at treatment start.
provenance reviewnot_startedThe recent-death rule does not apply (died 1985). Historical claims come from UPI, TIME, Cancer Today (AACR), Biography.com, and Encyclopedia.com. Birth-date conflicts from his own accounts are recorded as rejected alternatives. No statement or health fact is attributed to his relatives or colleagues; the histology, stage, biomarkers, and treatment are synthetic.
safe messaging reviewnot_startedTobacco claims are marked sensitive; his death is recorded without detail; the anti-smoking message is quoted as published.

Comments and corrections

Sign in with GitHub to comment on this record. To report a specific error, ideally with a source, use the feedback form; each report becomes a tracked issue.

Comments appear on the online version of this page.